Onkologie. 2019:13(5):221-224 | DOI: 10.36290/xon.2019.042

Chemotherapy alone no longer a treatment standard for advanced non-small cell lung cancer

Libor Havel
Pneumologická klinika 1. LF a TN, Thomayerova nemocnice Praha

Targeted therapy and immunotherapy are an unquestionable treatment standard for NSCLC in the first line. The decision concerning
NSCLC treatment requires the knowledge of results of predictive testing in all patients, with identification of predictive biomarkers
being an integral part of NSCLC diagnosis. In order to improve the prognosis of patients with NSCLC, it is necessary to provide precise
diagnostics that will allow identification of those eligible for targeted therapy and immunotherapy. Adjustment of effective cooperation
of individual workplaces with Comprehensive Cancer Centres will increase the availability of novel drugs for patients with NSCLC.

Keywords: NSCLC, predictive diagnosis, immunotherapy, pembrolizumab

Published: October 20, 2019  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Havel L. Chemotherapy alone no longer a treatment standard for advanced non-small cell lung cancer. Onkologie. 2019;13(5):221-224. doi: 10.36290/xon.2019.042.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. www.svod.cz
    2. Planchard D, Popat S, Kerr K, et, al. Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2019; 30(5): 863-870. Go to original source... Go to PubMed...
    3. Modrá kniha ČOS, verze platná od 1. 3. 2019. https://www.linkos.cz/lekar-a-multidisciplinarni-tym/diagnostika-a-lecba/modra-kniha-cos/aktualni-vydani-modre-knihy/25-8-zhoubny-novotvar-bronchu-a-plice-c34/.
    4. Průzkum společnosti IQVIA Patient W.A.I.T. Indicator 2018. The economic and societal footprint of the pharmaceutical industry in Europe (2019).
    5. Garon EB, Hellmann MD, Rizvi NA, et al. Five-Year Overall Survival for Patients With Advanced Non-Small-Cell Lung Cancer Treated With Pembrolizumab: Results From the Phase I KEYNOTE-001 Study. J Clin Oncol. 2019: JCO1900934. Go to original source... Go to PubMed...
    6. Myers G. Immune-related adverse events of immune checkpoint inhibitors: a brief review. Curr Oncol. 2018; 25(5): 342-347. Go to original source... Go to PubMed...
    7. Pakkala S, Ramalingam SS. Personalized therapy for lung cancer: striking a moving target. JCI Insight. 2018; 3(15). Go to original source... Go to PubMed...
    8. Reck M, Rodríguez-Abreu D, Robinson AG, et al. Updated Analysis of KEYNOTE-024: Pembrolizumab Versus Platinum-Based Chemotherapy for Advanced Non-Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score of 50 % or Greater. J Clin Oncol. 2019; 37(7): 537-546. Go to original source... Go to PubMed...
    9. Brahmer JR, Rodríguez-Abreu D, Robinson AG, et al. Health-related quality-of-life results for pembrolizumab versus chemotherapy in advanced, PD-L1-positive NSCLC (KEYNOTE-024): a multicentre, international, randomised, open-label phase 3 trial. Lancet Oncol. 2017; 18(12): 1600-1609. Go to original source... Go to PubMed...
    10. SPC přípravku Keytruda na www.sukl.cz.

    Return to the content


    Oncology

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.